帕唑帕尼
索拉非尼
医学
肿瘤科
内科学
酪氨酸激酶
酪氨酸激酶抑制剂
癌症
舒尼替尼
肝细胞癌
受体
作者
Jonathan Noujaim,Abha Gupta,Caroline L. Holloway,Ramy Saleh,Amirrtha Srikanthan,Christopher Lemieux,Hagit Peretz Soroka,Pauline Tibout,Robert Turcotte,Xiaolan Feng,Albiruni R. Abdul Razak,Philippos Apolinário Costa
标识
DOI：10.1016/j.ejca.2024.114119
摘要
Sorafenib and pazopanib, two tyrosine kinase inhibitors (TKI), are widely used in patients with progressive symptomatic desmoid tumors (DT). Limited real-word data is available on long-term outcomes of patients who progressed on, stopped, or continued TKIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI
爱静静
zzzyyy
乐乐乐乐乐乐
浅尝离白
shinysparrow
kento
景辣条
竹筏过海
YifanWang
研友_ZAVbe8
鬼见愁
吃不饱星球球长
徐叽钰
华仔
睡觉晒太阳
不配.
mmyhn
eternity136
sutharsons
从容芮
皖公网安备34019202002308
